These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1231 related articles for article (PubMed ID: 36546652)

  • 21. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
    Thondam SK; Cuthbertson DJ; Wilding JPH
    Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
    Gallwitz B
    Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists].
    Scheen A
    Rev Med Liege; 2024 Sep; 79(9):605-612. PubMed ID: 39262368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.
    Jakubowska A; Roux CWL; Viljoen A
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):12-22. PubMed ID: 38356208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
    Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus.
    Alqifari SF; Alkomi O; Esmail A; Alkhawami K; Yousri S; Muqresh MA; Alharbi N; Khojah AA; Aljabri A; Allahham A; Prabahar K; Alshareef H; Aldhaeefi M; Alrasheed T; Alrabiah A; AlBishi LA
    World J Diabetes; 2024 Mar; 15(3):331-347. PubMed ID: 38591071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tirzepatide: First Approval.
    Syed YY
    Drugs; 2022 Jul; 82(11):1213-1220. PubMed ID: 35830001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
    Dhir G; Cusi K
    J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy.
    Tschöp M; Nogueiras R; Ahrén B
    Diabetologia; 2023 Oct; 66(10):1796-1808. PubMed ID: 37209227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tirzepatide: A Review in Type 2 Diabetes.
    France NL; Syed YY
    Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
    Bernsmeier C; Meyer-Gerspach AC; Blaser LS; Jeker L; Steinert RE; Heim MH; Beglinger C
    PLoS One; 2014; 9(1):e87488. PubMed ID: 24489924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
    Soresi M; Giannitrapani L
    World J Gastroenterol; 2024 Aug; 30(30):3541-3547. PubMed ID: 39193573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
    Baggio LL; Drucker DJ
    Mol Metab; 2021 Apr; 46():101090. PubMed ID: 32987188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
    Gogineni P; Melson E; Papamargaritis D; Davies M
    Expert Opin Pharmacother; 2024 May; 25(7):801-818. PubMed ID: 38753454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Drug: Tirzepatide (Mounjaro
    Gettman L
    Sr Care Pharm; 2023 Feb; 38(2):50-62. PubMed ID: 36751934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How May GIP Enhance the Therapeutic Efficacy of GLP-1?
    Samms RJ; Coghlan MP; Sloop KW
    Trends Endocrinol Metab; 2020 Jun; 31(6):410-421. PubMed ID: 32396843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
    Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
    Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.